SETDB1 promotes glioblastoma growth via CSF-1 - dependent macrophage recruitment by activating the AKT/mTOR signaling pathway

Shuai Han  
China Medical University First Hospital

Wei Zhen  
People's Hospital of Liaoning Province

Tongqi Guo  
People's Hospital of Liaoning Province

Jianjun Zou  
People's Hospital of Liaoning Province

Fuyong Li  
The People's Hospital of China Medical University

Research

Keywords: SETDB1, glioblastoma, AKT/mTOR, TAMs, CSF-1

Posted Date: October 6th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-35583/v2

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published on October 15th, 2020. See the published version at https://doi.org/10.1186/s13046-020-01730-8.
Abstract

**Background:** Glioblastoma is a common disease of the central nervous system (CNS), with high morbidity and mortality. In the infiltrate in the tumor microenvironment, tumor-associated macrophages (TAMs) are abundant, which are important factors in glioblastoma progression. However, the exact details of TAMs in glioblastoma progression have yet to be determined.

**Methods:** The clinical relevance of SET domain bifurcated 1 (SETDB1) was analyzed by immunohistochemistry, real-time PCR and Western blotting of glioblastoma tissues. SETDB1-induced cell proliferation, migration and invasion were investigated by CCK-8 assay, colony formation assay, wound healing and Transwell assay. The relationship between SETDB1 and colony stimulating factor 1 (CSF-1), as well as TAMs recruitment was examined by Western blotting, real-time PCR and syngeneic mouse model.

**Results:** Our findings showed that SETDB1 upregulated in glioblastoma and relative to poor progression. Gain and loss of function approaches showed the SETDB1 overexpression promotes cell proliferation, migration and invasion in glioblastoma cells. However, knockdown SETDB1 exerted opposite effects *in vitro*. Moreover, SETDB1 promotes AKT/mTOR-dependent CSF-1 induction and secretion, which leads to macrophage recruitment in the tumor, resulted in tumor growth.

**Conclusion:** Our research clarified that SETDB1 regulates of tumor microenvironment and hence presents a potential therapeutic target for treating glioblastoma.

Introduction

Glioma is a tumor type that derived from glial cells, with a high incidence, high recurrence rate, and poor prognosis[1]. Previous research has demonstrated that gliomas account for 47.1% of primary malignant brain and other central nervous system tumors, of which glioblastoma is the main type of gliomas, accounting for about 56.1% of cases[2, 3]. The treatment process for glioma includes surgery followed by radiotherapy, with or without temozolomide (TMZ) chemotherapy[4, 5].

Previous studies have shown that the interaction between glioblastoma cells and tumor microenvironment plays an important role in glioblastoma progression[6]. Revealing the underlining mechanism of interaction between glioblastoma cells and tumor microenvironment components may be useful for the discovery of novel therapeutic targets[7, 8]. The tumor microenvironment is comprised of diverse nonmalignant stromal cell types that are associated with tumor progression and metastasis, such as tumor-associated macrophages (TAMs) of the hematopoietic lineage, which are abundant migratory cells[9, 10]. Macrophages roughly develop into two main groups with different functions in immune defense and immune surveillance called classically activated macrophages (M1) and alternatively activated macrophages (M2), both of which can transform into each other with the changes in the
The density of these cells has been shown to be related to the prognosis of several types of cancer, such as glioblastoma[12, 13]. The heterogeneous nature of these cells and their ability to show different responses to cues from the environment is indicative of their roles in cancer progression[14, 15].

The microenvironment is modulated by the chemokine profile at the tumor site, as this influences macrophage differentiation to hence affect the advancement of glioblastoma[16, 17]. Among these chemokines, colony stimulating factor 1 (CSF-1) is a ubiquitously produced factor seen in many tumors (including glioblastoma) that is vital for metastasis[18]. This factor causes the recruitment of TAMs and other cell subsets to influence the processes of inflammation, angiogenesis, proliferation and evasion of the immune response[19, 20]. The use of anti-CSF-1 antibodies has been shown to decrease the \textit{in vivo} tumor burden by 96%, according to preclinical cancer models[21].

SETDB1 (SET domain bifurcated 1) is encoded by the approximately 38.6 kb long \textit{SETDB1} gene located on human chromosome 1q21.3[22]. This protein is a member of the methyltransferase family of SET-domains (Su(var)3-9, E(z), Trithorax) that function by silencing genes or inhibiting transcription via H3K9 trimethylation[23]. SETDB1 is linked to embryonic development and is also a candidate for early Huntington disease therapy. Recently, research pointed out that SETDB1 is expressed at abnormal and high levels in melanoma, ovarian cancer, lung cancer, and breast cancer[24-28]. The involvement and function of SETDB1 in glioblastoma have yet to be well studied, which calls for studies in this direction.

In the current study, we identified that SETDB1 was markedly upregulated in glioblastoma and displayed a significant association with the clinicopathological characteristics and survival of glioblastoma patients. Overexpressing SETDB1 boosted the transcription of CSF-1 by activating the AKT/mTOR signaling pathway. Furthermore, SETDB1 induced CSF-1 expression in glioblastoma cells leading to the recruitment of TAMs and subsequent tumor growth. These finding indicate the role of SETDB1 in both oncogenesis and TAM recruitment in glioblastoma pathogenesis.

\textbf{Material And Methods}

\textbf{Cell culture and reagents}

American Type Culture Collection (ATCC, Manassas, VA, USA) was the source of glioblastoma cell lines: U87, U251, H4, A172, U118, LN229, SHG-44 and GL261. Cell culture was performed in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin (HyClone, Thermo, USA) at 37°C and 5% CO\textsubscript{2}. NHAs (Normal human astrocytes) were procured from Lonza (Switzerland) and cultured as per supplied instructions. Rapamycin (Selleckchem) and MK-2206 (Selleckchem) were diluted with DMSO (Sigma).

\textbf{Human glioblastoma samples}
Glioblastoma tissues (n = 40) and neighboring healthy tissues (n = 40) were surgically excised at The People's Hospital of China Medical University and the First Hospital of China Medical University. Table 1 displays the clinicopathological features of the patients. Regular follow-up was performed for patients along with informed consent. Other data included relapse-free survival and overall survival (OS). This work received approval from the ethics committee of The People's Hospital of China Medical University and the First Hospital of China Medical University.

**Immunohistochemistry (IHC)**

In accordance with previous works[29, 30], staining of tissues was performed with a SETDB1 antibody (Sigma-Aldrich, USA). The scoring of cells was performed in accordance with the following guide: 0 (no positive staining); 1 (1 to 25% positive cells); 2 (26 to 50% positive cells); 3 (51 to 75% positive cells); and 4 (> 75% positive cells). The scoring for staining intensity was performed as follows: 0, negative; 1, weak; 2, moderate; and 3, high. The formula for SETDB1-positive cells was as follows: staining intensity score × percentage. This score involved both the nucleus and cytoplasm and was analyzed by two pathologists.

**Cell invasion assay**

The migration assay used Falcon cell culture inserts from BD (Franklin, USA). The invasion assay utilized a BioCoat™ Matrigel™ Invasion Chamber (BD) in accordance with the instructions of the manufacturer. A phase contrast microscope was utilized to count cells; the average of 5 various fields/well was considered.

**Wound-healing assay**

Indicated ells were cultured in 6-well plates in triplicate for each cell line until approximately 90% confluent. Wounds were made in each confluent monolayer of cells with a sterile 200-μl pipette tip, and fresh growth medium was replaced. Microscopic pictures were taken of the same field at 24 hours.

**Macrophage migration assay**

The 24-well transwell plates (Corning Inc) were used to examine the macrophages migration induced by CM from U87 cells with indicated treatment. Macrophages were collected and added into the top chamber of 24-well transwell plates. Simultaneously, CM were added into the bottom of transwell chamber. After 24 hours, the cells that crossed the inserts were stained with crystal violet and counted under phase-contrast microscopy.

**CCK-8 assay**

The indicated cells (5,000 per well) were plated in 96-well plates and grown in normal culture conditions. Cell proliferation was determined every 24 hours for 4 days using a CCK-8 assay.

**Clone formation assay**
Six-well plates were used to plate single-cell suspensions at a density of 1,000 cells per plate. Every 3 days, the culture medium was replaced. After allowing 2 weeks for clone formation, fixation and staining of the clones was performed using 0.1% crystal violet/40% methanol. Microscopy was performed to count colonies with >50 cells/colony.

**RNA extraction and real-time PCR**

Real-time PCR was performed as previously described[31, 32]. Briefly, TRIzol (Invitrogen, USA) was utilized for the extraction of total RNA. cDNA was synthesized with the PrimeScript™ RT reagent kit (Takara, Dalian) in accordance with the instructions of the manufacturer. SYBR Premix ExTaq II (Takara, Dalian) was utilized for real-time PCR of this cDNA on an ABI PRISM 7300 (Applied Biosystems, USA) to analyze the chemokines of the immune system. GAPDH was used to normalize mRNA levels. The primers used are listed in Table 2.

**Transfection and Knockdown**

Transfections with targeted siRNA against AKT were performed using lipofectamine 3000 according to the manufacturer's instructions. Stable SETDB1 knockdown cells were generated by transducing U87 or U251 cells with the pLKO.1-puro lentiviral vector (Addgene) expressing shRNA. Lentiviral particles were generated by co-transfecting 293T cells with the lentiviral vector, pMD2.G (VSVG), pMDLg/pRRE, and pRSV-REV (Addgene). Following lentiviral transduction, cells were plated in 96-well plates in the presence of puromycin (2 μg/ml; EMD/Millipore). SETDB1 expression of the puromycin-resistant clones was then analyzed by Western blotting. The sequences are listed in Table 3.

**Western blotting**

Western blotting was performed as previously described[33, 34]. Briefly, cell lysis was performed with the RIPA buffer protein extraction reagent (Pierce, Rockford, IL, USA) containing a protease inhibitor cocktail (Roche, USA). The proteins were resolved by 10% SDS-PAGE followed by transfer to polyvinylidene fluoride (PVDF) membranes (Sigma-Aldrich). Next, the membranes were blocked using 5% bovine serum albumin (BSA) and incubated with primary antibodies at 4°C overnight. Appropriate secondary antibodies were later added and then visualized by using an ECL chemiluminescence kit. The primary antibodies used are listed as follows: SETDB1 (HPA018142, Sigma-Aldrich), cleaved caspase 3 (9661, Cell signaling technology), cleaved caspase 8 (9748, Cell signaling technology), slug (9585, Cell signaling technology), vimentin (5741, Cell signaling technology), E-cadherin (14472, Cell signaling technology), mTOR (2983, Cell signaling technology), p-mTOR (5536, Cell signaling technology), AKT (4685, Cell signaling technology), p-AKT (4060, Cell signaling technology), CSF-1 (3155, Cell signaling technology), β-actin (3700, Cell signaling technology).

**Macrophage cells isolation and differentiation**
The preparation of human monocytes from buffy coats of healthy volunteers was performed using Ficoll-Hypaque (Pharmacia Corporation) for 50 min at 400 g. Twenty-four-well plates were seeded with $2 \times 10^6$ cells/mL in RPMI 1640 medium containing 10% heat inactivated human AB serum, 50 U of penicillin/mL, 50 U of streptomycin/mL, 2 mM L-glutamine, and 100 ng/mL human M-CSF (which allows differentiation into macrophages). Warm medium was used to gently wash away non-adherent cells 6 days post-culture. CD14$^+$ macrophages were found to account for greater than 95% of the adherent cells. The activation of these monocytes to macrophages 

\textit{in vitro} \textit{involved the treatment of} $2 \times 10^6$ cells/L with 25 $\mu$g/mL lipopolysaccharide (LPS, Sigma-Aldrich) to produce M1-polarized macrophages and 45 ng/mL recombinant human interleukin-4 (IL-4; R&D) to produce M2-polarized macrophages. Flow cytometry was employed to detect the formation of macrophages. For the following \textit{in vitro} assays, cells were cultured for 24 hours with RPMI media minus supplements and meticulously washed with PBS prior to the experiments.

\textbf{Animal experiments}

For the xenograft model, $5 \times 10^5$ U251-EV, U251-SETDB1, U87-shCon or shSETDB1 cells in 100 $\mu$L of PBS was performed followed by subcutaneous injection in the flanks of nude mice. The mice were sacrificed 15 days and tumor weights were assessed. The mice were kept at the Mouse Experimentation Core premises of the China Medical University.

The syngeneic glioblastoma mouse model was generated in accordance with previous reports\[35, 36\]. Briefly, 2% isoflurane in O$_2$ was used to sedate C57BL/6J mice (4-6 weeks old). The addition of $5 \times 10^5$ GL261-EV and GL261-SETDB1 cells in 100 $\mu$L of PBS was performed followed by subcutaneous injection in the flanks of C57BL/6J mice. The mice were sacrificed after 19 days and tumor weights were assessed.

\textbf{Statistical analysis}

The mean ± standard deviation (SD) was used to represent the data of triplicate assays. Student’s $t$-test was applied to assess significant differences between groups. Repeated measures analysis of variance was performed to assess variations between tumor parameters (growth rate and cell growth) of the animals.

\textbf{Results}

\textit{SETDB1 is frequently overexpressed and predicts poor glioblastoma prognosis}

To investigate the role of SETDB1 in glioblastoma cells, the level of SETDB1 was assessed in glioblastoma patients. IHC and real-time PCR results demonstrated that SETDB1 was evidently increased in tumor samples compared with surrounding healthy tissues (\textit{Figure 1A and 1B}). Next, western blotting was employed to assess the protein level of SETDB1 in cell lines. Higher levels of SETDB1 were detected
in the glioblastoma cells in comparison with NHAs (Figure 1C). In addition, real-time PCR result showed that SETDB1 mRNA level was higher in glioblastoma cells than in NHAs cells (Figure 1D).

This was followed by studying the effect of this SETDB1 overexpression in the clinic. Increased mRNA expression of SETDB1 was evidently linked to shorter relapse-free glioblastoma survival, as shown by Kaplan-Meier curves (p=0.025; Figure 1E). Our findings indicate that age and sex had no association with SETDB1 expression and TNM stage were found to be linked with the protein expression (Table 1). SETDB1 was also found to serve as an independent factor for prognosis and shorter relapse-free survival, as shown by the multivariate Cox regression analysis (Table 4). Overall, high expression of SETDB1 was found to serve as a prognostic factor for glioblastoma.

**SETDB1 enhances the growth of glioblastoma and inhibits apoptosis**

We next investigated the biological functions of SETDB1 involved in U87 and U251 cells. We overexpression or knockdown SETDB1 in U87 and U251 cells with lenti-SETDB1, Lentiviruses with empty vector (EV), sh SETDB1 or negative control shRNA (shCon) transfection. The following changes in expression were assessed using real-time PCR and Western blotting (Figure 2A, 2B, S1A and S1B). Increased SETDB1 expression caused an evident increase in proliferation and clone formation in the cell lines studied compared with those in the controls (Figure 2C and 2D). SETDB1 silencing caused the opposite results: decreased cell division and clone formation (Figure S1C-S1F). Next, the effect of this ectopic expression on apoptosis was studies; increased expression of SETDB1 noticeably reduced the levels of the active (cleaved) forms of caspase-8 and caspase-3 and hence decreased apoptosis in the cell lines mentioned previously in the presence or absence of staurosporine (STS) or TRAIL (Figure 2E and S1G). The opposite results were seen when silencing SETDB1, as indicated by increased sensitivity to STS or TRAIL treatment and increased apoptosis and expression of its markers in U251 cells (Figure S1H and S1I).

Further investigation involved the subcutaneous injection of U251-EV and U251-SETDB1 into nude mice. This ectopic SETDB1 expression caused a conspicuous growth increase in tumors in the animals (Figure 2F). SETDB1 overexpression was confirmed by Western blotting (Figure 2G). Ki-67 assays showed that U251-SETDB1 xenografts displayed increased numbers of proliferating cells (Figure 2H). However, knockdown of SETDB1 caused an evident decrease in xenograft size (Figure S1J and S1K). Markedly decreased cell proliferation was observed in U87-shSETDB1 xenografts according to Ki-67 staining results (Figure S1L). Overall, SETDB1 is vital in the oncogenesis and advancement of glioblastoma.

**SETDB1 increases migration and invasion in glioblastoma cells**

Assays to assess the abilities of cells to migrate and invade were performed to examine the metastasis potential *in vitro*. The ability of cells to migrate and invade was augmented in the presence of ectopic SETDB1 expression in the U87 and U251 cell lines compared with the control (Figure 3A and 3B). Upregulation of Slug and Vimentin (mesenchymal markers) and downregulation of E-cadherin (an epithelial marker) were shown by western blotting (Figure 3C). The opposite results were observed for the
same cell lines that were subjected to silencing of SETDB1, which decreased the ability of the cells to invade (Figure 3D and 3E), decreased Slug and Vimentin and increased E-cadherin (Figure 3F). Moreover, overexpression of SETDB1 in stable SETDB1 cells attenuated SETDB1 silencing-induced invasion, migration suppression and EMT regulation (Figure 3D-3F). The above data suggest that SETDB1 regulates migration, invasion and EMT in glioblastoma.

**Increased SETDB1 promotes CSF-1 secretion from glioblastoma**

The levels of cytokines and chemokines CSF-1, TGF-β, IL-4, IL-13, and VEGF involved in the infiltration of TAMs were assessed through real-time PCR for SETDB1 in glioblastoma lines. U87 and U251 glioblastoma cells displayed elevated profiles of CSF-1 mRNA and proteins in the presence of SETDB1 overexpression (Figure 4A and 4B), while knockdown caused the opposite effects (Figure 4C and 4D). In addition, the ELISA demonstrated that SETDB1 promotes CSF-1 secretion (Figure 4E), as well as SETDB1 knockdown suppresses CSF-1 secretion (Figure 4F). As expected, CSF-1 expression significantly correlated with CD163 and SETDB1 expression in glioblastoma samples (Figure 4G and 4H). These observations are indicative of higher CSF-1 secretion due to elevated levels of SETDB1, which is in turn connected to increased TAMs in glioblastoma.

**SETDB1 promoted the secretion of CSF-1 by activating the AKT/mTOR signaling pathway**

Next, the potential involvement of the AKT/mTOR signaling pathway in the CSF-1 secretion caused by SETDB1 was assessed. Increased AKT and mTOR phosphorylation was shown by Western blotting when SETDB1 was overexpressed in glioblastoma lines, and this effect was reversed by administration of MK-2206 (Figure 5A and 5B). Similarly, knockdown of AKT expression using siRNA attenuated the increase of CSF-1 due to SETDB1 overexpression (Figure 5C and 5D). Moreover, Rapamycin, a mTOR inhibitor, attenuated SETDB1-induced CSF-1 upregulation in U87 and U251 cells (Figure 5E and 5F). To decipher the SETDB1/AKT/mTOR/CSF-1 axis in vivo, we performed Western blotting analysis on the tumor tissue from the xenograft model. We found that SETDB1 knockdown significantly reduced AKT activation and CSF-1 protein expression in the xenograft model, while SETDB1 overexpression remarkably promoted AKT activation and CSF-1 protein levels in xenograft tumor tissues (Figure 5G and 5H). Overall, these observations suggest the involvement of AKT/mTOR signaling in the increase in SETDB1-mediated CSF-1 synthesis. Hence, this axis can serve as a prognostic marker in patients.

**SETDB1 promotes recruitment and polarization of macrophages via CSF-1**

The involvement of this SETDB1-CSF-1 axis in macrophage infiltration was assessed by an in vitro migration assay using conditioned media (CM) from glioblastoma cells overexpressing SETDB1. Compared with control CM, CM from these cells was found to clearly augment the recruitment of macrophages (Figure 6A). Further, this recruitment was evidently suppressed when a CSF-1 antagonist was administered to macrophages. Overall, these results suggest that macrophage migration is mediated by SETDB1 via CSF-1 induction.
Next, the effect of SETDB1 on macrophage polarization via CSF-1 was assessed. The CM from glioblastoma cell lines overexpressing SETDB1 caused elevated expression of CD163 (a M2 macrophage marker) mRNA compared to that in cells cultured with control CM, while there was no change in the expression of CD68 (a M1 macrophage marker) (Figure 6B). Flow cytometry showed a similar protein profile (Figure 6C). The cytokine mRNAs and proteins that are representative of TAMs, IL-10, CCL17, and CCL22, were noticeably higher in TAMs incubated with CM from U87 cells with high SETDB1 expression than in TAMs incubated with CM from control cells (Figure 6D and 6E). In addition, we also analyzed M1-related genes and found macrophage incubated with CM from SETDB1 overexpression U87 cells does not affect IL-12, IL-23 and CXCL10 levels (Figure 6F and 6G). Overall, these data suggest a role for CSF-1 and SETDB1 in promoting macrophage entry and differentiation.

**SETDB1 promotes tumor growth in a TAM-dependent manner**

To demonstrate whether the oncogenic roles of SETDB1 in glioblastoma are TAM-dependent, we investigated the susceptibility of macrophages to liposomal clodronate treatment. For this, we overexpressed SETDB1 in the mouse glioblastoma cell line GL261, which showed faint SETDB1 protein expression (Figure 7A). Next, we performed a syngeneic mouse model study with injection of SETDB1-overexpressing and control cell lines into the C57BL/6J mice. Prior to injection, liposomes containing clodronate or PBS were administered for two weeks and continued for additional 19 days after tumor implantation (Figure 7B). The clodronate treatment caused a suppression in mSETDB1-induced F4/80+ macrophages infiltration in the glioblastoma tumors of the animals (Figure 7C and 7D). The increased tumor burden induced by SETDB1 overexpression was largely attenuated in mice that received clodronate liposomes (Figure 7E and 7F). Moreover, no significant difference in the body weights between these four groups was observed during the course of the experiment (Figure 7G). The above data suggested that the tumor-promoting effects of SETDB1 in glioblastoma are, at least in part, mediated by macrophage infiltration of the tumor microenvironment.

**Discussion**

The progression of glioblastoma involves the role of interconnected glioblastoma cells and TAMs in the tumor microenvironment[37]. This increase in infiltrates is connected to the poor prognosis of glioblastoma[5]. The function of this system is yet to be characterized; thus, further studies are warranted to identify such patterns to rapidly unearth potential molecules that may serve as therapeutic tools[13]. In the current study, we revealed that SETDB1 is involved in the modulation of the tumor microenvironment of glioblastoma progression. SETDB1 was found to promote CSF-1 expression and secretion by activating the AKT/mTOR pathway. Moreover, SETDB1-induced CSF-1 modulated the tumor microenvironment by recruiting TAMs to glioblastoma tissues, leading to tumor growth (Figure 7H). These findings reveal opportunities for research on the role of SETDB1 in disease progression.

SETDB1 functions as a histone methyltransferase to cause histone H3K9 trimethylation, which is involved in the formation of heterochromatin[38]. These H3K9 and H3K27 sites are connected to
transcriptional regulation and epigenetics[39]. This presents an opportunity to target epigenetic modifiers such as SETDB1 to treat malignancies. Research has identified the overexpression of SETDB1 in many malignancies, such as glioblastoma, melanoma, prostate cancer, and breast cancer (BRC), which was linked to cancer cell division as well as metastasis[23, 26, 38]. Previously study have shown that SETDB1 in macrophages potently suppresses Toll-like receptor 4 (TLR4)-mediated expression of proinflammatory cytokines including interleukin-6 through its methyltransferase activity[40]. However, a complete picture is lacking in this area of cancer studies.

Our study focuses on the association of TAMs with cancer cells in the tumor microenvironment[41, 42]. These cells have been shown to synthesize several factors that modulate cancer cell division and angiogenesis according to recent studies[43]. Particularly, the presence of symbiosis between macrophages and tumor cells has been shown by experiments where coculture of these cells caused the degradation of collagen[44]. Previous study has shown that macrophage recruitment plays a key role in GABRP-mediated tumor progression in pancreatic cancer[45]. TAMs also involved in tumor growth in glioblastoma[45, 46]. The results from this work highlight several novel features of the mechanisms underlying glioblastoma. Such features of TAMs facilitate research targeting these cells in response to disease. CSF-1 and its receptor, colony-stimulating factor 1 receptor (CSF-1R), are areas of concern and are being developed in clinical research[47]. One feature that is encouraging here is identification of safe applications of immunotherapeutic or standard treatment tools[48-50]. Such promising activity has been demonstrated in autocrine CSF-1-based benign diffuse-type tenosynovial giant cell tumors[51, 52]. In the case of malignant disorders, reports from clinical perspectives have yet to be explored.

Continuous research facilitates the understanding that distinct macrophage features, such as functions and phenotypes, are a reflection of various signals (for differentiation, polarization, survival or recruitment) in a tissue-specific environment[53]. The implication here is that targeting TAMs for therapy would show variation according to the organ in which the cells are present[54, 55]. This work showed that SETDB1 promotes CSF-1 induction and secretion by tumor cells and CSF-1 is involved in tumor progression and TAM infiltration. The origin of CSF-1 can be traced back to circulating monocytes in the blood vessels of the tumor. This provides the possibility that CSF-1 and its sustained production could serve as a target for efficient disease treatment. Consistence with previous study[56], our findings showed that the increase in SETDB1 promotes CSF-1 induction via AKT/mTOR activation. Interestingly, our results also demonstrated that silencing of AKT also reduces CSF-1 levels, in both U87 and U251 cell lines (Figure 5C and D). Therefore, our findings indicated that AKT may induce CSF-1 expression independently of SETDB1. Hence, this work proposes a molecular mechanism for CSF-1 overexpression in glioblastoma, opening up the possibility for this molecule or its receptor to be a target in patients with SETDB1-overexpressing glioblastoma. In this study, we used two mouse model, xenograft and syngeneic mouse model, which were established from intrathecal cancer cell injection. Due to the cancer cells are injected in a place with a completely different tumor microenvironment, very far from tumor microenvironment can be found in the CNS. Therefore, orthotopic tumor model is needed to confirm our results in the future.
Conclusion

In the current study, our findings indicated that SETDB1 upregulated in glioblastoma and relative to poor progression. Overexpression of SETDB1 promotes proliferation, invasion and migration. Our findings also indicated that SETDB1 promotes macrophage recruitment and polarization via AKT/mTOR-dependent CSF-1 induction and secretion. Our results indicated that SETDB1 is essential for glioblastoma tumorigenesis, and may be a newly target for treatment and prognostic evaluation in glioblastoma, which will be the focus of our future investigations.

List Of Abbreviations

ATCC: American Type Culture Collection; BSA: bovine serum albumin; CM: conditioned media; CNS: central nervous system; CSF-1: colony stimulating factor 1; CSF-1R: colony-stimulating factor 1 receptor; DMEM: Dulbecco's modified Eagle's medium; ELISA: enzyme-linked immunosorbent assay; EV: empty vector; FBS: fetal bovine serum; IHC: Immunohistochemistry; NHAs: Normal human astrocytes; OS: overall survival; PVDF: polyvinylidene fluoride; SD: standard deviation; SETDB1: SET domain bifurcated 1; TAMs: tumor-associated macrophages; TMZ: temozolomide.

Declarations

Acknowledgements

None

Authors’ contributions

SH, WZ, TG, JZ and FL were involved in the experimental design, acquisition of data, analysis and interpretation of data, and drafting of the manuscript. SH, WZ and FL were involved in the experimental design and acquisition of xenografts. SH and FL were involved in the study conception and design, analysis and interpretation of data, revision of the manuscript, and study supervision.

Funding

None

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Ethics approval and consent to participate

This study was approved by the Ethical Committee of The People's Hospital of China Medical University (The People's Hospital of Liaoning Province).
Consent for publication

Informed consent was obtained from all individual participants included in the study.

Competing interests

The authors declare that they have no conflicts of interest.

References

1. Hanif, F., et al., Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev, 2017. 18(1): p. 3-9.

2. Wood, M.D., A.M. Halfpenny, and S.R. Moore, Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. Diagn Pathol, 2019. 14(1): p. 29.

3. Lukas, R.V., et al., Newly Diagnosed Glioblastoma: A Review on Clinical Management. Oncology (Williston Park), 2019. 33(3): p. 91-100.

4. Bahadur, S., et al., Current promising treatment strategy for glioblastoma multiform: A review. Oncol Rev, 2019. 13(2): p. 417.

5. Davis, M.E., Glioblastoma: Overview of Disease and Treatment. Clin J Oncol Nurs, 2016. 20(5 Suppl): p. S2-8.

6. Pombo Antunes, A.R., et al., Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife, 2020. 9.

7. De Vleeschouwer, S. and G. Bergers, Glioblastoma: To Target the Tumor Cell or the Microenvironment?, in Glioblastoma, S. De Vleeschouwer, Editor. 2017: Brisbane (AU).

8. Schiffer, D., et al., Glioblastoma: Microenvironment and Niche Concept. Cancers (Basel), 2018. 11(1).

9. Chen, Y., et al., Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci, 2019. 26(1): p. 78.

10. Lin, Y., J. Xu, and H. Lan, Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol, 2019. 12(1): p. 76.

11. Lee, C., et al., Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. J Immunother Cancer, 2019. 7(1): p. 147.

12. Wei, C., et al., Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer, 2019. 18(1): p. 64.

13. Erreni, M., A. Mantovani, and P. Allavena, Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer. Cancer Microenviron, 2011. 4(2): p. 141-54.

14. Aras, S. and M.R. Zaidi, TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer, 2017. 117(11): p. 1583-1591.
15. Georgoudaki, A.M., et al., Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. Cell Rep, 2016. 15(9): p. 2000-11.

16. Kim, Y.B., et al., Programming of macrophages by UV-irradiated apoptotic cancer cells inhibits cancer progression and lung metastasis. Cell Mol Immunol, 2019. 16(11): p. 851-867.

17. Nielsen, S.R. and M.C. Schmid, Macrophages as Key Drivers of Cancer Progression and Metastasis. Mediators Inflamm, 2017. 2017: p. 9624760.

18. Pinto, M.L., et al., The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer. Front Immunol, 2019. 10: p. 1875.

19. Wang, J., et al., Crosstalk between cancer and immune cells: Role of tumor-associated macrophages in the tumor microenvironment. Cancer Med, 2019. 8(10): p. 4709-4721.

20. Farajzadeh Valilou, S., et al., The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer. Cytokine Growth Factor Rev, 2018. 39: p. 46-61.

21. Cannarile, M.A., et al., Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer, 2017. 5(1): p. 53.

22. Karanth, A.V., et al., Emerging role of SETDB1 as a therapeutic target. Expert Opin Ther Targets, 2017. 21(3): p. 319-331.

23. Yang, W., et al., SETDB1 induces epithelialmesenchymal transition in breast carcinoma by directly binding with Snail promoter. Oncol Rep, 2019. 41(2): p. 1284-1292.

24. Torrano, J., et al., Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming. Clin Epigenetics, 2019. 11(1): p. 43.

25. Cruz-Tapias, P., et al., Expression of the Major and Pro-Oncogenic H3K9 Lysine Methyltransferase SETDB1 in Non-Small Cell Lung Cancer. Cancers (Basel), 2019. 11(8).

26. Ryu, T.Y., et al., SETDB1 regulates SMAD7 expression for breast cancer metastasis. BMB Rep, 2019. 52(2): p. 139-144.

27. Wang, W., et al., Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer. Onco Targets Ther, 2019. 12: p. 7451-7457.

28. Orouji, E., et al., Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target. Int J Cancer, 2019. 145(12): p. 3462-3477.

29. Tong, J., et al., Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins. Cancer Res, 2018. 78(16): p. 4704-4715.

30. Tong, J., et al., Mcl-1 Degradation Is Required for Targeted Therapeutics to Eradicate Colon Cancer Cells. Cancer Res, 2017. 77(9): p. 2512-2521.

31. Tan, X., et al., Tim-4 promotes the growth of colorectal cancer by activating angiogenesis and recruiting tumor-associated macrophages via the PI3K/AKT/mTOR signaling pathway. Cancer Lett, 2018. 436: p. 119-128.
32. Tong, J., et al., FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene, 2017. 36(6): p. 787-796.

33. Zhang, Z., et al., GNA13 promotes tumor growth and angiogenesis by upregulating CXC chemokines via the NF-kappaB signaling pathway in colorectal cancer cells. Cancer Med, 2018. 7(11): p. 5611-5620.

34. Tong, J., et al., FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors. Mol Cancer Ther, 2017. 16(9): p. 1979-1988.

35. Xu, H., et al., Six1 promotes colorectal cancer growth and metastasis by stimulating angiogenesis and recruiting tumor-associated macrophages. Carcinogenesis, 2017. 38(3): p. 281-292.

36. Zhang, J., et al., Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature, 2018. 553(7686): p. 91-95.

37. Zhang, R., et al., Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. Cell Death Dis, 2019. 10(4): p. 273.

38. Ropa, J., et al., SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation. Haematologica, 2019.

39. Keniry, A., et al., Setdb1-mediated H3K9 methylation is enriched on the inactive X and plays a role in its epigenetic silencing. Epigenetics Chromatin, 2016. 9: p. 16.

40. Hachiya, R., et al., The H3K9 methyltransferase Setdb1 regulates TLR4-mediated inflammatory responses in macrophages. Sci Rep, 2016. 6: p. 28845.

41. Chanmee, T., et al., Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel), 2014. 6(3): p. 1670-90.

42. Solinas, G., et al., Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol, 2009. 86(5): p. 1065-73.

43. Zhu, J., et al., The Role of Tumor Associated Macrophages in the Tumor Microenvironment: Mechanism and Functions. Anticancer Agents Med Chem, 2016. 16(9): p. 1133-41.

44. Madsen, D.H., et al., Tumor-Associated Macrophages Derived from Circulating Inflammatory Monocytes Degrade Collagen through Cellular Uptake. Cell Rep, 2017. 21(13): p. 3662-3671.

45. Jiang, S.H., et al., GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner. Gut, 2019. 68(11): p. 1994-2006.

46. An, Z., et al., EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res, 2018. 78(24): p. 6785-6794.

47. Richardsen, E., et al., Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality. Anticancer Res, 2015. 35(2): p. 865-74.

48. Saung, M.T., et al., Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer, 2018. 6(1): p. 118.
49. Mao, K., et al., Intratumoral delivery of M-CSF by calcium crosslinked polymer micelles enhances cancer immunotherapy. Biomater Sci, 2019. 7(7): p. 2769-2776.

50. Shi, G., et al., Modulating the Tumor Microenvironment via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy. Mol Ther, 2019. 27(1): p. 244-260.

51. Ho, J., et al., Detection of CSF1 rearrangements deleting the 3' UTR in tenosynovial giant cell tumors. Genes Chromosomes Cancer, 2020. 59(2): p. 96-105.

52. Tap, W.D., et al., Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med, 2015. 373(5): p. 428-37.

53. Kumar, V., et al., Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors. Cancer Cell, 2017. 32(5): p. 654-668 e5.

54. Brown, J.M., L. Recht, and S. Strober, The Promise of Targeting Macrophages in Cancer Therapy. Clin Cancer Res, 2017. 23(13): p. 3241-3250.

55. Zhu, Y., et al., CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res, 2014. 74(18): p. 5057-69.

56. Wang, G., et al., SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. Nat Cell Biol, 2019. 21(2): p. 214-225.

Tables

| Table 1. Clinicopathologic Features of SETDB1 expression in glioblastoma |
|---------------------------------------------------------------|
|                  | Low SETDB1 level (n=40) | High SETDB1 level (n=40) | p value  |
|------------------|--------------------------|--------------------------|----------|
| Age              | 55 ± 13.33               | 57 ± 12.65               | 0.432    |
| Gender           |                          |                          | 0.469    |
| Male             | 24                       | 29                       |          |
| Female           | 16                       | 11                       |          |
| TNM stage        |                          |                          | 0.001    |
| I, II            | 32                       | 7                        |          |
| III, IV          | 8                        | 33                       |          |
| Table 2. Real-time PCR primers |
|-------------------------------|
| **SETDB1**                    |
| Forward 5'-GGAGGA ACTTCGT CATCATTG-3' |
| Reverse 5'-TCTTTTCTGTAG ACCG TC-3' |
| **CSF-1**                     |
| Forward 5'-AGTATGGC AAGG AGTG CAG-3' |
| Reverse 5'-ATCTGG CATGA GTCTCCATT-3' |
| **TGF-β**                     |
| Forward 5'-AAGAAGTC ACCCGGTG CTA-3' |
| Reverse 5'-TGTTGTGATG CTTTGTTTGTCA-3' |
| **IL-8**                      |
| Forward 5'-GTGCAGTTTT GGCAAGGAGT-3' |
| Reverse 5'-TTATGAAT TCTCAGC CCTTCAAAAACT TCTC-3' |
| **IL-4**                      |
| Forward 5'-CCGTAACAGACAT CTTT GCTGCC-3' |
| Reverse 5'-GAGTGTC CTTTCTCAGT GGTGCT-3' |
| **IL-13**                     |
| Forward 5'-CCTCTGAC CTTAAGGAGCTTAT-3' |
| Reverse 5'-CCTTGCA CAGGAGGTCTT-3' |
| **VEGF**                      |
| Forward 5'-CAAGCCAAGGCG GTGAGCCA-3' |
| Reverse 5'-TCTGCCGGAGTC TCGCCCT-3' |
| **CCL2**                      |
| Forward 5'-AGGTGTCCCA AAAGAAGCTGA-3' |
| Reverse 5'-ATGTCTGG ACCCATT CTTCT-3' |
| **CCL20**                     |
| Forward 5'-TCCTGGCTG GCTTTGATG TCA-3' |
| Reverse 5'-CAAAGTTTGCTTGCTTCTGTA-3' |
| **CD86**                      |
| Forward 5'-TCTCACCAGGA AACAGCATCT-3' |
| Reverse 5'-CTTACGGAAGC ACCCATGAT-3' |
| **CD163**                     |
| Forward 5'-TCCACAGTCC AAGCAGTC-3' |
| Reverse 5'-CCTTGGA AACAGAGA CAGGC-3' |
| **IL-10**                     |
| Forward 5'-ATGCTGC TCTGCTTTA CTGACTG-3' |
| Reverse 5'-CCCAAGTA ACCCTTAAAGTC CTCG-3' |
| **CCL17**                     |
| Forward 5'-AGGGACCTG CACACAGAGAC-3' |
| Reverse 5'-AGGTAGTCCC GGGAGACAGT-3' |
| **CCL22**                     |
| Forward 5'-TGCCATCAGTTTAGTGAAGG-3' |
| Reverse 5'-CGGCAGGATT TTGGAGGTCCA-3' |
GAPDH
| Forward  | 5′-AATGGATTTGGACGCAATGGT-3′ |
| Reverse  | 5′-TTTGCACTGGTACGTGTTGAT-3′ |

### Table 3. Knockdown sequence

| Target sequence | si AKT | sh SETDB1 |
|-----------------|--------|-----------|
| si AKT          | GGAGGGUUGGCUUGCAACAAA |
| sh SETDB1       | GGTGATGAGTACTTTGCCA |

### Table 4. Cox regression analysis for relapse-free survival in glioblastoma patients

|                               | Univariate analysis |                      | Multivariate analysis |                      |
|-------------------------------|---------------------|----------------------|-----------------------|----------------------|
|                               | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value |
| SETDB1 expression (high vs. low) | 2.234 (0.981-4.128) | 0.023 | 2.459 (1.232-5.483) | 0.018 |
| Age                           | 1.321 (0.548-2.325) | 0.563 | 1.431 (0.674-2.543) | 0.554 |
| Male vs. Female               | 1.453 (0.674-3.092) | 0.345 | 1.543 (0.783-3.482) | 0.323 |
| Stage (III, IV vs. I, II)     | 1.982 (1.128-3.763) | 0.007 | 1.889 (1.093-3.542) | 0.011 |

### Figures
Figure 1

SETDB1 was upregulated in glioblastoma tissues and corelative with poor tumor progression. (A) Representative IHC staining of SETDB1 protein expression in glioblastoma tumor tissues (T) and adjacent normal tissue (N) of three patients. Scale bar: 50 µm. (B) mRNA level of SETDB1 was analyzed by real-time PCR in glioblastoma tumor tissues (T) and adjacent normal tissue (N) of patients. (C) Western blotting of SETDB1 expression in NHAs and indicated glioblastoma cells. (D) mRNA level of SETDB1 was analyzed by real-time PCR in NHAs and indicated glioblastoma cells. (E) Kaplan-Meier survival analysis indicated that glioblastoma patients with high expression of SETDB1 had worse relapse-free survival.
Figure 2

SETDB1 promotes cell growth, and apoptosis in vitro and in vivo. (A) mRNA level of SETDB1 in indicated cells transfected with SETDB1 plasmid or control vector. (B) Western blotting of SETDB1 in indicated cells transfected with SETDB1 plasmid or control vector. (C) CCK-8 of indicated cells transfected with SETDB1 plasmid or control vector. (D) Colony formation of indicated cells transfected with SETDB1 plasmid or control vector. (E) Western blotting of indicated proteins in U251 cells transfected with SETDB1 plasmid or control vector treated with 500 nM staurosporine (STS) for 24 hours. (F) Ectopic expression of SETDB1 accelerated growth of U251 xenografts in nude mice (n=6) as compared to controls. (G) Western blotting of ectopic expression of SETDB1 in tumors from U251-SETDB1 groups. (H) Representative images of Ki67-positive cells in vector and SETDB1 transfected tumors. Scale bar: 50 µm. Results were expressed as means ± SD of 3 independent experiments. **, P<0.01.
Figure 3

SETDB1 promotes invasion, migration and EMT of glioblastoma cells. (A) Representative images of matrigel invasion assay revealed that ectopic expression of SETDB1 promoted glioblastoma cells invasion. Scale bar: 100 μm. (B) Representative images of wound-healing assay indicated that ectopic expression of SETDB1 promoted cell migration in glioblastoma cells. Scale bar: 100 μm. (C) Western blotting of mesenchymal markers (Slug and Vimentin) and epithelial markers (E-cadherin) in cells transfected with SETDB1 or control plasmid. Scale bar: 100 μm. (D) Representative images of matrigel invasion assay revealed that downregulation of SETDB1 suppressed glioblastoma cells invasion. Scale bar: 100 μm. (E) Representative images of wound-healing assay indicated that downregulation of
SETDB1 suppressed cell migration in glioblastoma cells. (F) Western blotting of mesenchymal markers (Slug and Vimentin) and epithelial markers (E-cadherin) in cells transfected with stable shRNA against SETDB1. Results were expressed as means ± SD of 3 independent experiments. **, P<0.01.

Figure 4

SETDB1 regulates CSF-1 level in glioblastoma cells. (A) Real-time PCR for mRNA level of genes coding for tumor-associated macrophage (TAMs) recruitment associated cytokines in U87 cells with SETDB1
overexpression. (B) Real-time PCR for mRNA level of genes coding for tumor-associated macrophage (TAMs) recruitment associated cytokines in U251 cells with SETDB1 overexpression. (C) Real-time PCR for mRNA level of genes coding for tumor-associated macrophage (TAMs) recruitment associated cytokines in U87 cells with SETDB1 knockdown. (D) Real-time PCR for mRNA level of genes coding for tumor-associated macrophage (TAMs) recruitment associated cytokines in U251 cells with SETDB1 knockdown. (E) Enzyme-linked immunosorbent assay (ELISA) analysis of CSF-1 concentration in the supernatants of cultured glioblastoma cells with SETDB1 overexpression. (F) Enzyme-linked immunosorbent assay (ELISA) analysis of CSF-1 concentration in the supernatants of cultured glioblastoma cells with SETDB1 knockdown. (G) TCGA database indicated the correlation of CD163 and CSF-1 in glioblastoma tissues. (H) TCGA database indicated the correlation of SETDB1 and CSF-1 in glioblastoma tissues. Results were expressed as means ± SD of 3 independent experiments. **, P<0.01.
Figure 5

PI3K/AKT signaling pathway mediated SETDB1-induced CSF-1 induction. (A) Western blotting of indicated proteins in U87 cells transfected with SETDB1 overexpression with or without MK-2206 pretreatment. (B) Western blotting of indicated proteins in U251 cells transfected with SETDB1 overexpression with or without MK-2206 pretreatment. (C) Western blotting of indicated proteins in U87 cells transfected with SETDB1 overexpression with or without siRNA against AKT. (D) Western blotting of
indicated proteins in U251 cells transfected with SETDB1 overexpression with or without siRNA against AKT. (E) Western blotting of indicated proteins in U87 cells transfected with SETDB1 overexpression with or without rapamycin pretreatment. (F) Western blotting of indicated proteins in U251 cells transfected with SETDB1 overexpression with or without rapamycin pretreatment. (G) Western blotting of indicated proteins in control and SETDB1 overexpression xenograft tumors. (H) Western blotting of indicated proteins in control and SETDB1 knockdown xenograft tumors.

Figure 6
SETDB1 promotes macrophage recruitment and polarization. (A) Transwell migration assay of macrophage by CM from indicated U87 cells. (B) Real-time PCR for the expression levels of CD68 and CD163 in macrophages treated with CM from U87 cells as indicated. (C) Flow cytometry analysis for the expression levels of CD163 in macrophages treated with CM from glioblastoma cells as indicated. (D) Real-time PCR for the mRNA expression of tumor-associated macrophage (TAM) characteristic cytokines in macrophages treated with CM from glioblastoma cells as indicated. (E) Enzyme-linked immunosorbent assay (ELISA) for the secretion of tumor-associated macrophage (TAM) characteristic cytokines in macrophages treated with CM from U87 cells as indicated. (F) Real-time PCR for the mRNA expression of M1-related cytokines in macrophages treated with CM from U87 cells as indicated. (G) Enzyme-linked immunosorbent assay (ELISA) for the secretion of M1-related cytokines in macrophages treated with CM from U87 cells as indicated. Results were expressed as means ± SD of 3 independent experiments. **, P<0.01.
Figure 7

SETDB1 promotes tumor growth in a macrophage-dependent manner. (A) Western blotting of SETDB1 overexpression efficiency in GL261 cells. (B) Treatment scheme depicting intraperitoneal application of clodronate liposomes or phosphate-buffered saline (PBS) liposomes in C57BL/6J mice for 4 weeks. GL261 cells were administered at the end of week 2 and animals were sacrificed 2 weeks later. (C) Representative immunohistochemistry of F4/80+ cells in sections from tumors obtained from C57BL/6J
mice treated with clodronate liposomes or PBS liposomes. Scale bar: 50 µm. (D) Tumor volume of vector and SETDB1 overexpression tumors from clodronate-liposome or PBS-liposome-treated mice (n=6 per group). (E) Tumor weight of vector and SETDB1 overexpression tumors from clodronate-liposome or PBS-liposome-treated mice (n=6 per group). (G) The body weight of mice of indicated groups. (H) A working model of how SETDB1 regulates TAMs recruitment and tumor growth in glioblastoma.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementaldata.docx